THE EFFECTIVENESS AND COST EFFECTIVENESS OF PLERIXAFOR plus GCSF VERSUS GCSF ± CHEMOTHERAPY AS SALVAGE MOBILIZATION REGIMENS IN LYMPHOMA AND MULTIPLE MYELOMA PATIENTS

被引：0
|
作者：
Tuffaha, H. W. [1 ]
Hussein, A. A. [1 ]
Sharma, S. [1 ]
Abu-Jazar, H. [1 ]
Al-Rawi, O. S. [1 ]
Saad, A. M. [1 ]
Al-Zaben, A. [1 ]
Hussein, N. [1 ]
Abdel-Rahman, F. A. [1 ]
机构：
[1] FA King Hussein Canc Ctr, Amman, Jordan
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2012年 / 18卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2011.12.130
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
118
引用
收藏
页码：S247 / S247
页数：1
相关论文
共 50 条
  • [1] GCSF with or without chemotherapy compared to Plerixafor with GCSF as salvage mobilization regimen in patients with multiple myeloma and lymphoma: Collection effectiveness and cost effectiveness analysis
    Abdel-Rahman, Fawzi
    Tuffaha, Haitham W.
    Sharma, Shanta
    Abu Jazar, Husam
    Hussein, Nilly
    Saad, Adnan
    Al Rawi, Omar
    Hussein, Ayad
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2014, 20 (02) : 130 - 136
  • [2] COMPARATIVE COST UTILITY ANALYSIS OF PLERIXAFOR PLUS GCSF VERSUS CYCLOPHOSPHAMIDE PLUS GCSF AS SALVAGE MOBILIZATION REGIMENS IN MULTIPLE MYELOMA PATIENTS
    Tuffaha, H. W.
    Hussein, A. A.
    Abdel-Rahman, F. A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S248 - S248
  • [3] COST-EFFECTIVENESS OF PLERIXAFOR PLUS GCSF FOR MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH MYELOMA AND LYMPHOMA IN SPAIN
    Duarte, R. F.
    Perez-Simon, J. A.
    Martin, G.
    de la Rubia, J.
    Marin, P.
    Alvarez, M. A.
    Espinos, B.
    Roset, M.
    VALUE IN HEALTH, 2012, 15 (07) : A423 - A423
  • [4] Are We Choosing Mobilization Regimens for Autologous Stem Cell Transplantation in Multiple Myeloma Wisely?: A Single Centre Comparison of GCSF plus /-Plerixafor Vs Cyclophosphamide/GCSF plus /- Plerixafor
    Yang, Chloe
    Dehghani, Mina
    Hopman, Wilma
    Bhella, Sita D.
    BLOOD, 2019, 134
  • [5] Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF plus /-plerixafor vs cyclophosphamide/GCSF plus /-plerixafor
    Yang, Chloe
    Dehghani, Mina
    Hopman, Wilma
    Bhella, Sita
    JOURNAL OF CLINICAL APHERESIS, 2022, 37 (04) : 348 - 353
  • [6] Comparison of CD34+ collections in patients with multiple myeloma using etoposide/cyclophosphamide plus GCSF cyclophosphamide plus GCSF, and GCSF alone mobilization regimens
    Scott, LM
    Brougher, LI
    Anderson-Reitz, LA
    Ensley, L
    Saracino, G
    Agura, ED
    Berryman, RB
    Fay, JW
    Pineiro, L
    Vance, EA
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 121 - 121
  • [7] CYCLOPHOSPHAMIDE PRIMING WITH INTRAVENOUS PLERIXAFOR AND GCSF MOBILIZATION FOR MULTIPLE MYELOMA
    Krishnan, A.
    Wang, S.
    Htut, M.
    Farol, L.
    Palmer, J.
    Quazi, I
    Forman, S.
    Tsai, N.
    Forman, S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S262 - S262
  • [8] Cost-Effectiveness of Hematopoietic Stem Cell Mobilization Strategies Including Plerixafor in Multiple Myeloma and Lymphoma Patients
    Ales, Tichopad
    Veronika, Vitova
    Zdenek, Koristek
    Daniel, Lysak
    JOURNAL OF CLINICAL APHERESIS, 2013, 28 (06) : 395 - 403
  • [9] Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis
    Carlo Lazzaro
    Luca Castagna
    Francesco Lanza
    Daniele Laszlo
    Giuseppe Milone
    Luca Pierelli
    Riccardo Saccardi
    Bone Marrow Transplantation, 2021, 56 : 1876 - 1887
  • [10] Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis
    Lazzaro, Carlo
    Castagna, Luca
    Lanza, Francesco
    Laszlo, Daniele
    Milone, Giuseppe
    Pierelli, Luca
    Saccardi, Riccardo
    BONE MARROW TRANSPLANTATION, 2021, 56 (08) : 1876 - 1887
12345